Vmn2r21 activators encompass a diverse chemical class designed to engage with the Vmn2r21 receptor, a member of the G-protein coupled receptor (GPCR) family. These activators target the receptor's signaling pathways, aiming to elicit a cellular response by modulating the receptor's interaction with its associated G-proteins. The activation process often involves the increase of intracellular cAMP or calcium levels, which serve as secondary messengers in the signaling cascade initiated by the receptor. Compounds that increase cAMP generally do so by enhancing the activity of adenylyl cyclase or by inhibiting the activity of phosphodiesterases, enzymes responsible for cAMP degradation. The elevation of cAMP within the cell can amplify the signaling cascades that follow GPCR activation, thereby affecting the activity of Vmn2r21.
Furthermore, activators in this class can influence the receptor's signaling by altering the concentrations of intracellular calcium, another pivotal secondary messenger. This can be achieved by either direct modulation of calcium channels or by affecting the enzymes that regulate the synthesis and degradation of molecules involved in calcium signaling. Additionally, some activators may interact with protein kinases such as PKC, which play a significant role in the phosphorylation and subsequent regulation of GPCR activity. The precise modulation of these pathways ensures that Vmn2r21 activators can affect the receptor's function, ultimately leading to a cascade of intracellular events. This fine-tuning of receptor signaling is central to the function of Vmn2r21 activators, allowing them to control the receptor's activity without the need for the receptor's natural ligand. Through these methods of action, the compounds classified as Vmn2r21 activators exert their influence on the cellular processes governed by this receptor.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific phosphodiesterase inhibitor, increases cAMP and cGMP by preventing their degradation, which could possibly activate Vmn2r21s by enhancing GPCR signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol ester that activates protein kinase C (PKC), which could possibly activate Vmn2r21s by modulating GPCR function. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
Cell-permeable calcium chelator, could possibly activate Vmn2r21s by modulating intracellular calcium levels and thus affecting calcium-signaling pathways downstream of GPCRs. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor, leads to increased cytosolic calcium concentrations, which could possibly activate Vmn2r21s by influencing calcium signaling. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Alters the function of Ryanodine receptors, could possibly activate Vmn2r21s by modifying intracellular calcium release. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
Modulator of IP3 receptors and store-operated calcium entry, could possibly activate Vmn2r21s by influencing calcium signaling pathways associated with GPCR activation. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
ADP-ribosylates Gi alpha subunit, inhibiting its activity, which could possibly activate Vmn2r21s by affecting associated signaling pathways. | ||||||
Carbachol | 51-83-2 | sc-202092 sc-202092A sc-202092C sc-202092D sc-202092B sc-202092E | 1 g 10 g 25 g 50 g 100 g 250 g | $122.00 $281.00 $388.00 $683.00 $1428.00 $3060.00 | 12 | |
A cholinergic agonist that can activate muscarinic acetylcholine receptors, which could possibly activate Vmn2r21s by influencing GPCR-mediated signaling pathways. | ||||||